Hereby, the bone marrow of WT donors (pretreated with 5-fluorouracil in the case of CML and AML, but not B-ALL) is transduced with retroviri expressing BCR-ABL1 (for CML and B-ALL) or MLL-AF9 (for AML) and transplanted into WT or ANXA2-KO recipients. Here, ANXA2 is linked to acute myeloid leukemia.